Narrow search
Showing 1 - 10 of 7,314
Cover Image
How health care reform affects pharmaceutical research and development
Cook, Anna (contributor); Webre, Philip C. (contributor) - 1994
Persistent link: https://www.econbiz.de/10000426441
Cover Image
Are settlements in patent litigation collusive? : evidence from paragraph IV challenges
Helland, Eric; Seabury, Seth A. - 2016
Persistent link: https://www.econbiz.de/10011476934
Cover Image
US healthcare reform and the pharmaceutical industry
Daemmrich, Arthur - 2011
Persistent link: https://www.econbiz.de/10009316337
Cover Image
Negotiating NAFTA : explaining the outcome in culture, textiles, autos, and pharmaceuticals
Robert, Maryse - 2000
Persistent link: https://www.econbiz.de/10001483047
Cover Image
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives : Italy as a case study
Armeni, Patrizio; Jommi, Claudio; Otto, Monica - In: The European journal of health economics : HEPAC ; … 17 (2016) 8, pp. 963-977
Persistent link: https://www.econbiz.de/10011660118
Cover Image
Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany
Herr, Annika; Suppliet, Moritz - 2012
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
Cover Image
Ex-post assessment of merger effects : the case of Pfizer and Pharmacia (2003)
Leheyda, Nina; Beschorner, Patrick Frank Ernst; … - 2011
The paper studies the effects of the Pfizer and Pharmacia (2003) merger on competition in the Swiss pharmaceutical market and compares the assessment of the Swiss Competition Commission (COMCO) with the post-merger market developments. We find that the merger has had a miniscule impact on the...
Persistent link: https://www.econbiz.de/10009011228
Cover Image
Indirect Marketing für Pharmaunternehmen
Sandmann, Christoph - 2014
Die steigende Informationsflut erschwert es dem Marketing zunehmend zum Unternehmenserfolg beizutragen. Das … Pharmamarketing unterliegt dabei zusätzlichen Einschränkungen. Indirect Marketing (IM) stellt als Bestandteil des … Marketing (IL) umfassen Leistungen, welche nicht der Hauptleistungserstellung und -verwertung entspringen, mit dieser jedoch in …
Persistent link: https://www.econbiz.de/10010256206
Cover Image
The Impact of Pharmaceutical Policy Measures : A Structural-Break Approach
Barros, Pedro P.; Nunes, Luis C. - 2009
Pharmaceutical spending in many other countries has had a steep increase in the last decade. The Portuguese Government has adopted several measures to reduce pharmaceutical expenditure growth, ranging from increased co-payments to price decreases determined administratively. Promotion of generic...
Persistent link: https://www.econbiz.de/10014209702